Oric Pharmaceuticals Inc (ORIC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Oric Pharmaceuticals Inc (ORIC) has a cash flow conversion efficiency ratio of -0.078x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-32.44 Million) by net assets ($415.56 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Oric Pharmaceuticals Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Oric Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Oric Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Oric Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oric Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Amerigo Resources Ltd.
TO:ARG
|
0.111x |
|
Shenzhen Sunnypol Optoelectronics Co Ltd
SHE:002876
|
-0.042x |
|
Ton Yi Industrial Corp
TW:9907
|
0.042x |
|
Heritage Commerce Corp
NASDAQ:HTBK
|
0.028x |
|
Abacus Life Inc.
NASDAQ:ABL
|
-0.075x |
|
MBK Public Company Limited
BK:MBK
|
0.042x |
|
Xencor Inc
NASDAQ:XNCR
|
-0.049x |
|
Allmed Medical Products Co Ltd Class A
SHE:002950
|
0.055x |
Annual Cash Flow Conversion Efficiency for Oric Pharmaceuticals Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Oric Pharmaceuticals Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see Oric Pharmaceuticals Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $384.36 Million | $-113.37 Million | -0.295x | +36.35% |
| 2024-12-31 | $243.12 Million | $-112.66 Million | -0.463x | -21.19% |
| 2023-12-31 | $224.09 Million | $-85.69 Million | -0.382x | -13.15% |
| 2022-12-31 | $222.35 Million | $-75.14 Million | -0.338x | -54.94% |
| 2021-12-31 | $272.98 Million | $-59.54 Million | -0.218x | -39.62% |
| 2020-12-31 | $289.78 Million | $-45.27 Million | -0.156x | +41.60% |
| 2019-12-31 | $87.97 Million | $-23.53 Million | -0.267x | -183.32% |
| 2018-12-31 | $-64.43 Million | $-20.68 Million | 0.321x | +139.65% |
| 2017-12-31 | $25.73 Million | $-20.83 Million | -0.810x | -- |
About Oric Pharmaceuticals Inc
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target… Read more